This database contains 1063 studies, archived under the term: "female"
Click here to filter this large number of results.
Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment
Abbatecola, Angela M.,
Lattanzio, Fabrizia,
Molinari, Anna M.,
Cioffi, Michele,
Mansi, Luigi,
Rambaldi, Pierfrancesco,
DiCioccio, Luigi,
Cacciapuoti, Federico,
Canonico, Raffaele,
Paolisso, Giuseppe
Objective: Studies have suggested that insulin resistance plays a role in cognitive impairment in individuals with type 2 diabetes. We aimed to determine whether an improvement in insulin resistance could explain cognitive performance variations over 36 weeks in older individuals with mild cognitive impairment (MCI) and type 2 diabetes.; Research Design and Methods: A total […]
Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study
Zheng, Ling,
Mack, Wendy J.,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Stroup, T. Scott,
Sultzer, David L.,
Tariot, Pierre N.,
Vigen, Cheryl,
Schneider, Lon S.
Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.; Method: The authors assessed 186 male and 235 female Alzheimer’s disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) […]
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease
Wilkinson, David,
Schindler, Rachel,
Schwam, Elias,
Waldemar, Gunhild,
Jones, Roy W.,
Gauthier, Serge,
Lopez, Oscar L.,
Cummings, Jeffrey,
Xu, Yikang,
Feldman, Howard H.
Background: Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer’s disease (AD).; Methods: Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10-27] were pooled from 3 randomized, double-blind placebo-controlled studies. Clinical […]
A practice-based intervention to improve primary care for falls, urinary incontinence, and dementia
Wenger, Neil S.,
Roth, Carol P.,
Shekelle, Paul G.,
Young, Roy T.,
Solomon, David H.,
Kamberg, Caren J.,
Chang, John T.,
Louie, Rachel,
Higashi, Takahiro,
MacLean, Catherine H.,
Adams, John,
Min, Lillian C.,
Ransohoff, Kurt,
Hoffing, Marc,
Reuben, David B.
Objectives: To determine whether a practice-based intervention can improve care for falls, urinary incontinence, and cognitive impairment.; Design: Controlled trial.; Setting: Two community medical groups.; Participants: Community-dwelling patients (357 at intervention sites and 287 at control sites) aged 75 and older identified as having difficulty with falls, incontinence, or cognitive impairment.; Intervention: Intervention and control […]
Effects of insulin and octreotide on memory and growth hormone in Alzheimer’s disease
Watson, G. Stennis,
Baker, Laura D.,
Cholerton, Brenna A.,
Rhoads, Kristoffer W.,
Merriam, George R.,
Schellenberg, Gerard D.,
Asthana, Sanjay,
Cherrier, Monique,
Craft, Suzanne
Both insulin alone and the somatostatin analogue octreotide alone facilitate memory in patients with Alzheimer’s disease (AD). Since octreotide inhibits endogenous insulin secretion, the cognitive effects of insulin and octreotide may not be independent. This study tested the individual and interactive effects of insulin and octreotide on memory and plasma growth hormone (GH) levels in […]
The effect of multisensory stimulation on persons residing in an extended care facility
Background: Non-pharmacological interventions, such as multisensory stimulation environments (MSSE), have demonstrated the ability to reduce inappropriate behavior among individuals with Alzheimer’s disease.; Methods: In this study, we compared the incidences of problematic behavior among individuals with Alzheimer’s disease residing in a long-term care facility who were and were not exposed to an MSSE. Retrospective data […]
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]
Group reminiscence intervention in Taiwanese elders with dementia
The purpose of this study was to evaluate the effect of structured group reminiscence therapy on behavior competence and physical functioning and to compare effectiveness of the intervention by stage of dementia in Taiwanese elders residing in institutional settings. A longitudinal experimental design was used. Seventy-seven Taiwanese elderly participants completed the study; 38 in the […]